In this Medscape commentary, Dr. Scott Kopetz of MD Anderson unpacks the rising role of ctDNA in colorectal cancer. Unlike traditional risk factors, ctDNA offers a real-time snapshot of tumor biology with powerful prognostic value. From guiding adjuvant therapy decisions in stage 2 and 3 disease to detecting recurrence months before imaging, the test is reshaping how oncologists think about surveillance and trial design. With sensitivity still evolving and novel therapies on the horizon, is ctDNA about to become the new backbone of CRC management?
Trending
- Gastroenterology Practice Economics: Benchmark 2026 (Jiro Health)
- Surgery Partners to be taken private by Bon Secours affiliate in $5.7 billion deal (Reuters)
- Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians (Guardant Health)
- Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer (Genmab)
- Do Wearables in GI Care Provide Useful Data or Fuel Anxiety? (Medscape)
- APPs Poised to Level the Playing Field for Rural Patients With IBD (GI & Endoscopy News)
- Improve IBD bowel checks for early cancer detection, study finds (Eurekalert)
- Blue Cross and Blue Shield of Texas leaves Medicare Advantage as UnitedHealthcare splits with Florida health systems (Medical Economics)
